Biagio Ricciuti

Biagio Ricciuti: Adjuvant/Neoadjuvant vs Perioperative Chemo-Immunotherapy in Resectable NSCLC at RomeLung25

Biagio Ricciuti, Thoracic Medical Oncologist at Dana-Farber Cancer, shared a post on X:

“Thoughtful presentations by Federico Cappuzzo and Solange Peters dissecting pros and cons of adjuvant/neoadjuvant vs perioperative chemo-immunotherapy in resectable NSCLC at RomeLung25”

More posts featuring RomeLung25.